{
  "docId": "019de073-742c-704c-a810-4500da4f1d81",
  "docSlug": "e78883ddf681fdb15564423388c7a078",
  "documentTitle": "Allarity Therapeutics | Investor Conference Presentation Deck | 23 slides",
  "authorId": "allarity-therapeutics",
  "authorName": "Allarity Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 23,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 48,
  "notes": "The table uses checkmarks and X marks to highlight the competitive advantage of Stenoparib.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-742c-704c-a810-4500da4f1d81/15",
  "deckHref": "/decks/019de073-742c-704c-a810-4500da4f1d81",
  "deckJsonHref": "/decks/019de073-742c-704c-a810-4500da4f1d81.json",
  "deckAnchorHref": "/decks/019de073-742c-704c-a810-4500da4f1d81#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Value Proposition: Allarity PARP inhibitor (Stenoparib) with exclusive DRP®: a novel, multi-targeted drug (Tankyrase and PARP inhibition) with improved efficacy, low myelotoxicity, and less drug resistance resulting in improved patient outcomes",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fe1ec94-08f6-49e2-8255-fb5c5ea8c5ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.1,
        "y": 0.15
      },
      "kind": "quote",
      "text": "\"... the identification of reliable biomarkers will be critical for the success of this targeted agent\" 1",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bcf0847-be03-48f4-992c-00af45d868f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1) Lars M. Wagner, \"Profile of veliparib and its potential in the treatment of solid tumors.\" Onco Targets Ther. 2015; 8: 1931–1939. 2) NCT03878849",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a58f23f2-b9bd-4258-a89a-debc6f7136a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "table",
      "text": "Competitive landscape matrix comparing Olaparib, Niraparib, Veliparib, Rucaparib, Talazoparib, and Stenoparib across 8 attributes.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18147073-79ce-40b7-a12b-3d36408d7f01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Stenoparib: Well Positioned in PARP Competitive Landscape",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7dfe323-4271-405f-aa63-93606fdb8736",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "76885097-e950-4493-9e51-1d219b14ea55",
      "evidence": "The slide features a table comparing Stenoparib with other PARP inhibitors across various attributes.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "9aec670b-c131-426f-9546-f67b51f80177",
      "evidence": "Table comparing product features across competitors",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 23,
      "from": 10,
      "beatId": "b256bbaf-5ead-4fee-9327-1e3695ac93a7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation presents DRP as a solution to the problem, highlighting its potential to personalize cancer care and improve patient outcomes.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}